Trikafta and Pulmonary function test abnormal - a phase IV clinical study of FDA data

Summary:

Pulmonary function test abnormal is reported as a side effect among people who take Trikafta (elexacaftor, ivacaftor, tezacaftor; ivacaftor), especially for people who are female, 60+ old, also take Pulmozyme, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Pulmonary function test abnormal when taking Trikafta. It is created by eHealthMe based on reports of 11,845 people who have side effects when taking Trikafta from the FDA, and is updated regularly.

What is Trikafta?

Trikafta has active ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor. eHealthMe is studying from 11,852 Trikafta users. Check the latest studies of Trikafta.

What is Pulmonary function test abnormal?

Pulmonary function test abnormal is found to be associated with 297 drugs and 320 conditions by eHealthMe. Check the latest studies of Pulmonary function test abnormal.

On Jul, 24, 2026

11,845 people reported to have side effects when taking Trikafta.
Among them, 16 people (0.14%) have Pulmonary function test abnormal.

Could Trikafta cause Pulmonary function test abnormal?

Among these 16 people:

What is the gender of people who have Pulmonary function test abnormal when taking Trikafta? *

female: 93.33 %
male: 6.67 %

What is the age of people who have Pulmonary function test abnormal when taking Trikafta? *

What are other drugs people take besides Trikafta? *

What are other side effects people have besides Pulmonary function test abnormal? *

Diarrhea: 4 people, 25.00%
Cough: 3 people, 18.75%
Depression: 2 people, 12.50%
Fatigue (feeling of tiredness): 2 people, 12.50%
Otitis (ear infection): 2 people, 12.50%
Wound Infection: 1 person, 6.25%
Malaise (a feeling of general discomfort or uneasiness): 1 person, 6.25%
Hypermetropia (abnormal condition in which vision for distant objects is better than for near objects): 1 person, 6.25%
Infection: 1 person, 6.25%
Intestinal Obstruction: 1 person, 6.25%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 15 people, 93.75%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 3 people, 18.75%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 3 people, 18.75%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 12.50%
Pneumonia Bacterial (pneumonia associated with bacterial infection): 2 people, 12.50%
Embolism Venous (embolus may pass into the arterial system): 2 people, 12.50%
Diabetes: 2 people, 12.50%
Asthma: 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Trikafta and have Pulmonary function test abnormal?

- Check whether Pulmonary function test abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Trikafta:

Trikafta (11,852 reports)

Pulmonary function test abnormal treatments and more:

Pulmonary function test abnormal (2,136 reports)

How severe was Pulmonary function test abnormal and when was it recovered:

Pulmonary function test abnormal in Trikafta

Expand to all the drugs that have ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor:

Pulmonary function test abnormal and drugs with ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trikafta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary function test abnormal:

Pulmonary function test abnormal (297 drugs)

Browse all the conditions that are associated with Pulmonary function test abnormal:

Pulmonary function test abnormal (320 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on elexacaftor, ivacaftor, tezacaftor; ivacaftor (the active ingredients of Trikafta) and Trikafta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.